<i>Annals of the Rheumatic Diseases</i>collection on glucocorticoids (2020–2023): novel insights and advances in therapy

Bijlsma, Johannes W J

doi:10.1136/ard-2023-224847

Cited by 2 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, appropriate treatment varies considerably for different indications for such treatment, as discussed for initial doses in the guidelines. 7,8 It is clear that individual patient characteristics may require dosage adaptation or more frequent and longer monitoring for AEs. 5,7…”

Section: • Pulse Therapy > 250 Mg Of Prednisone Equivalent Per Day Fo...mentioning

confidence: 99%

“…7,8 It is clear that individual patient characteristics may require dosage adaptation or more frequent and longer monitoring for AEs. 5,7…”

Section: • Pulse Therapy > 250 Mg Of Prednisone Equivalent Per Day Fo...mentioning

confidence: 99%

“…Therefore, it is emphasized that the risk of OP fracture increases with the simultaneous use of oral GCs and PPIs. 7 It is quite "difficult to find" a dose of GC that is safe for bones in RD. Thus, in the study by Adami et al 33 in patients who were prescribed long-term GC therapy without anti-OP drugs, a decrease in bone mineral density (BMD) was observed.…”

Section: Glucocorticoid-induced Osteoporosismentioning

confidence: 99%

“…6 Approximately one in three patients with inflammatory RD is treated for a short or longer period with the use of GC. 7,8 The debate regarding the acceptable balance between efficacy and safety (often of low doses) of GC in the treatment of inflammatory RD is as old as the treatment itself. 1…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Glucocorticoids in rheumatology: myths vs. reality

Rekalov,

Golovach,

Briner

et al. 2024

MOJOR

View full text Add to dashboard Cite

Glucocorticoids (GC) have been the mainstay of practicing rheumatologists since the Nobel Prize was awarded for the discovery of cortisone in 1950. It has been proven that GC have highly effective anti-inflammatory and immunosuppressive properties. Identification of genomic and non-genomic effects, which directly affect most pathogenetic processes in the course of rheumatic diseases, served as the basis for the implementation of GC in routine rheumatological therapy. The further widespread introduction of GC into rheumatology practice is due to low cost, high availability, quick onset of action, and activity aimed at preventing organ damage. The optimal choice for the use of GC in the treatment of rheumatic diseases is a specific and individual approach in dosage and routine monitoring. To date, there are no reliable tools for determining the toxicity of GC, which is associated with poor compliance, acute onset or chronic course of adverse events AE, variability in the duration of GC use, and the need for the different dosages to control diseases.

show abstract

Section: • Pulse Therapy > 250 Mg Of Prednisone Equivalent Per Day Fo...mentioning

confidence: 99%

“…7,8 It is clear that individual patient characteristics may require dosage adaptation or more frequent and longer monitoring for AEs. 5,7…”

Section: • Pulse Therapy > 250 Mg Of Prednisone Equivalent Per Day Fo...mentioning

confidence: 99%

Section: Glucocorticoid-induced Osteoporosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations